| Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis G Brandi, S De Lorenzo, M Nannini, S Curti, M Ottone, FG Dall’Olio, ... World journal of gastroenterology 22 (2), 519, 2016 | 107 | 2016 |
| Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept S De Lorenzo, F Tovoli, MA Barbera, F Garuti, A Palloni, G Frega, ... Scientific reports 8 (1), 9997, 2018 | 97 | 2018 |
| Microbiota, NASH, HCC and the potential role of probiotics G Brandi, S De Lorenzo, M Candela, MA Pantaleo, S Bellentani, F Tovoli, ... Carcinogenesis 38 (3), 231-240, 2017 | 93 | 2017 |
| Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis A Rizzo, G Frega, AD Ricci, A Palloni, F Abbati, S De Lorenzo, M Deserti, ... In vivo 34 (2), 479-488, 2020 | 75 | 2020 |
| Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience G Brandi, A Rizzo, FG Dall’Olio, C Felicani, G Ercolani, M Cescon, ... International Journal of Hyperthermia 37 (1), 479-485, 2020 | 71 | 2020 |
| Second-line treatment in advanced biliary tract cancer: today and tomorrow A Rizzo, AD Ricci, N Tober, MC Nigro, M Mosca, A Palloni, F Abbati, ... Anticancer research 40 (6), 3013-3030, 2020 | 66 | 2020 |
| Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation F Trevisani, G Brandi, F Garuti, MA Barbera, R Tortora, A Casadei Gardini, ... Journal of Cancer Research and Clinical Oncology 144, 403-414, 2018 | 60 | 2018 |
| How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: an updated systematic review and meta-analysis A Rizzo, AD Ricci, G Frega, A Palloni, S De Lorenzo, F Abbati, V Mollica, ... in vivo 34 (4), 1701-1714, 2020 | 50 | 2020 |
| Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma F Tovoli, V Dadduzio, S De Lorenzo, L Rimassa, G Masi, M Iavarone, ... Liver Cancer 10 (4), 370-379, 2021 | 44 | 2021 |
| Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role S De Lorenzo, F Tovoli, A Mazzotta, F Vasuri, J Edeline, D Malvi, ... Cancers 12 (11), 3182, 2020 | 44 | 2020 |
| Treatment of combined hepatocellular and cholangiocarcinoma S Leoni, V Sansone, S De Lorenzo, L Ielasi, F Tovoli, M Renzulli, ... Cancers 12 (4), 794, 2020 | 43 | 2020 |
| Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients G Brandi, M Deserti, F Vasuri, A Farioli, A Degiovanni, A Palloni, G Frega, ... The Oncologist 21 (5), 600-607, 2016 | 42 | 2016 |
| Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? G Brandi, AD Ricci, A Rizzo, C Zanfi, S Tavolari, A Palloni, S De Lorenzo, ... Cancer Communications 40 (9), 461, 2020 | 33 | 2020 |
| Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort U Peretti, A Cavaliere, M Niger, G Tortora, MC Di Marco, MG Rodriquenz, ... ESMO open 6 (1), 100032, 2021 | 28 | 2021 |
| Specific toxicity of maintenance olaparib versus placebo in advanced malignancies: a systematic review and meta-analysis AD Ricci, A Rizzo, M Novelli, S Tavolari, A Palloni, N Tober, F Abbati, ... Anticancer Research 40 (2), 597-608, 2020 | 27 | 2020 |
| Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in patients with hepatocellular carcinoma S De Lorenzo, F Tovoli, F Trevisani Cancers 14 (19), 4616, 2022 | 22 | 2022 |
| The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation M Ravaioli, A Cucchetti, AD Pinna, V De Pace, F Neri, MA Barbera, ... Scientific reports 7 (1), 11305, 2017 | 19 | 2017 |
| Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: where are we now? F Tovoli, S De Lorenzo, F Trevisani Vaccines 8 (4), 578, 2020 | 18 | 2020 |
| Regorafenib for the treatment of hepatocellular carcinoma. F Tovoli, A Granito, S De Lorenzo, L Bolondi Drugs of Today (Barcelona, Spain: 1998) 54 (1), 5-13, 2018 | 18 | 2018 |
| Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey G Orsi, M Di Marco, A Cavaliere, M Niger, S Bozzarelli, G Giordano, ... ESMO open 6 (5), 100238, 2021 | 17 | 2021 |
